报告名称：Hengrui Medicine(600276)Core business grew steadily new products and overseas ex
报告类型：点评报告
报告日期：2016-04-14
研究机构：中信证券国际
股票名称：恒瑞医药
股票代码：600276
页数：4
简介：Reiterate BUY. The Company has a comprehensive presence given its five major product lines, with a deep pipeline of innovative drugs; it outperforms domestic peers in terms of a global presence. We maintain 2016-17E EPS estimates at Rmb1.37/1.74, and project 2018E EPS of Rmb2.19. We arrive at a target price of Rmb61.65, equivalent to 45x 2016E PE. Reiterate BUY.
下载地址：Hengrui Medicine(600276)Core business grew steadily new products and overseas ex
